Navigation Links
Human Papillomavirus (HPV) High Risk, Paraffin

ProductsHuman Papillomavirus (HPV) High Risk, Paraffin
Company ARUP Laboratories
Item Human Papillomavirus (HPV) High Risk, Paraffin
Features 
Description ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' clients include more than half of the nation's university teaching hospitals and children's hospitals, major commercial laboratories, military and government facilities, and major clinics.
Info ARUP Laboratories
Customer Service: (800) 522-2787
Web site: http://www.aruplab.com

Related medicine products :

1. EPO EIA Human Cytokines 021-SDX021 Erythropoietin Anemia
2. Human Growth Hormone EIA Endocrine Function 025-BC-1033
3. Human Ferritin
4. Human Chorionic Gonadotropin (HCG) ELISA Kit
5. Human PSA ELISA Kit
6. Human Myoglobin Enzyme Immunoassay
7. Human Cardiac-Specific Troponin-I Enzyme Immunoassay (cTnI ELISA)
8. Antigen-Antibody Pen For Human Primary antibodies
9. Lyphochek Unassayed Chemistry Control (Human)
10. Liquichek Unassayed Chemistry Control (Human)
11. Human Growth Hormone (hGH)
Breaking Medicine Technology:Ameritox(R) Appoints Jay B. Zimmerman as Chief Operating Officer 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Bayer Consumer Care Voluntarily Recalls One Lot of Combination Package of Alka-Seltzer Plus(R) Day & Night Cold Formula Liquid Gels 2Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 1Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 2Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 3Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 4Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 5Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 6Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 7Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 8Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 9Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 10Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 11ULURU Inc to Present Altrazeal 28TM 29 Clinical Evidence at the American Podiatric Medical Association 28APMA 29 Annual Scientific Meeting in Toront 53161 1ULURU Inc to Present Altrazeal 28TM 29 Clinical Evidence at the American Podiatric Medical Association 28APMA 29 Annual Scientific Meeting in Toront 53161 2ULURU Inc to Present Altrazeal 28TM 29 Clinical Evidence at the American Podiatric Medical Association 28APMA 29 Annual Scientific Meeting in Toront 53161 3Regence Wins Awards for Consumer Appeal to Transform Health Care 53156 1Regence Wins Awards for Consumer Appeal to Transform Health Care 53156 2